Scienture (SCNX) Projected to Release Earnings on Wednesday

Scienture (NASDAQ:SCNX) is projected to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect Scienture to post earnings of ($1.57) per share and revenue of $1.22 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Scienture (NASDAQ:SCNX) last posted its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($2.25) by $2.18. The firm had revenue of $0.34 million during the quarter, compared to the consensus estimate of $1.96 million. On average, analysts expect Scienture to post ($4.44) EPS for the current fiscal year and ($0.27) EPS for the next fiscal year.

Scienture Trading Up 6.8%

Shares of Scienture stock opened at $3.45 on Wednesday. Scienture has a 12-month low of $2.64 and a 12-month high of $27.75. The company has a 50-day simple moving average of $6.02 and a 200 day simple moving average of $9.12. The company has a current ratio of 3.04, a quick ratio of 2.97 and a debt-to-equity ratio of 0.15.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Maxim Group set a $6.00 price objective on shares of Scienture and gave the stock a “buy” rating in a research note on Friday, October 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scienture in a report on Monday, September 21st. Finally, Zacks Research upgraded shares of Scienture to a “hold” rating in a research note on Friday, October 2nd. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $6.00.

About Scienture

Scienture Holdings, Inc is a specialty pharmaceutical company focused on developing and commercializing medicines for central nervous system disorders. The company seeks to address unmet treatment needs through pharmaceutical products and drug-delivery technologies designed to improve patient convenience and therapeutic use.

Scienture’s areas of interest include conditions such as insomnia, attention-deficit/hyperactivity disorder, anxiety, depression and pain. Its portfolio includes product candidates and commercial opportunities involving alternative delivery formats, including oral formulations and sprays.

The company serves the pharmaceutical market primarily in the United States.